XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition (Tables)
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table represents Evolent’s revenue disaggregated by line of business and product type (in thousands):
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2024202320242023
Medicaid$214,627 $195,259 $646,819 $587,611 
Medicare238,527 208,166 794,160 474,535 
Commercial and other168,246 107,590 467,220 345,695 
Total$621,400 $511,015 $1,908,199 $1,407,841 
Performance Suite$435,100 $323,722 $1,344,920 $840,171 
Specialty Technology and Services Suite85,474 81,230 255,992 223,598 
Administrative Services59,396 68,713 178,735 229,534 
Cases41,430 37,350 128,552 114,538 
Total$621,400 $511,015 $1,908,199 $1,407,841 
Schedule of Contract with Customer, Asset and Liability
The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of September 30, 2024 and December 31, 2023 (in thousands):
September 30, 2024December 31, 2023
Short-term receivables (1)
$406,786 $446,220 
Short-term deferred revenue2,621 5,976 
Long-term deferred revenue293 1,173 
————————
(1)Excludes pharmacy rebate receivable and pharmacy claims receivable.

Changes in deferred revenue for the nine months ended September 30, 2024 are as follows (in thousands):
Deferred revenue
Balance as of beginning-of-period$7,149 
Reclassification to revenue, as a result of performance obligations satisfied(5,041)
Cash received in advance of satisfaction of performance obligations806 
Balance as of end of period$2,914